74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
BioMarin Pharmaceutical Inc
Closed
SectorHealthcare
54.57 -0.26
Overview
Share price change
24h
Min
53.99
Max
55.18
Income | 241M 426M |
|---|---|
Sales | 80M 825M |
P/E Sector Avg | 15.935 35.739 |
EPS | 1.44 |
Profit margin | 51.637 |
Employees | 3,040 |
EBITDA | 95M 319M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +77.7% upside |
Next Earnings | 28 Oct 2025 |
|---|
Market Cap | -1.2B 10B |
|---|---|
Previous open | 54.83 |
Previous close | 54.57 |
News Sentiment
By Acuity
20%
80%
42 / 371 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
BioMarin Pharmaceutical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
BioMarin Pharmaceutical Inc Forecast
Price Target
By TipRanks
77.7% upside
12 Months Forecast
Average 97.2 USD 77.7%
High 122 USD
Low 60 USD
Based on 22 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.
Sentiment
By Acuity
42 / 371 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Live chat